Vontobel Holding Ltd. Sells 9,261 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Vontobel Holding Ltd. lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 53,309 shares of the medical research company's stock after selling 9,261 shares during the quarter. Vontobel Holding Ltd.'s holdings in IQVIA were worth $10,476,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Impax Asset Management Group plc grew its stake in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IQVIA by 3.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company's stock worth $290,545,000 after purchasing an additional 39,772 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE IQV traded down $0.17 during trading hours on Tuesday, hitting $193.27. 1,439,138 shares of the stock were exchanged, compared to its average volume of 1,376,622. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The company's 50 day moving average is $200.15 and its 200 day moving average is $217.43. The firm has a market capitalization of $35.08 billion, a P/E ratio of 25.77, a P/E/G ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company's stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on IQV shares. Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective for the company. Morgan Stanley upped their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Finally, Robert W. Baird reduced their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.